MarketCap
Facebook
X
Telegram
Harvard Bioscience Revenue | HBIO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Harvard Bioscience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 86.6 M | 94.1 M | 112 M | 113 M | 119 M | 102 M | 116 M | 121 M | 102 M | 105 M | 109 M | 109 M | 105 M | 111 M | 109 M | 108 M | 85.8 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 121 M | 85.8 M | 106 M |
Quarterly Revenue Harvard Bioscience
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.4 M | 20.8 M | - | 20.6 M | 20.4 M | 21.8 M | - | 22 M | 23.1 M | 24.5 M | - | 25.4 M | 28.8 M | 30 M | - | 26.9 M | 29.2 M | 28.8 M | - | 29.7 M | 29.2 M | 27 M | - | 24 M | 23.3 M | 23.8 M | 31 M | 27.4 M | 29.6 M | 28.2 M | 33.9 M | 28.6 M | 31.5 M | 26.8 M | 21.6 M | 18.7 M | 19 M | 18.1 M | 26.4 M | 25 M | 26.1 M | 27 M | 28.4 M | 25.7 M | 28.8 M | 25.8 M | 30.4 M | 25.4 M | 27 M | 27 M | 27.9 M | 25.1 M | 26.1 M | 26.1 M | 28.2 M | 26.1 M | 28.5 M | 28.3 M | 29 M | 26.4 M | 27.1 M | 26.3 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 33.9 M | 18.1 M | 26.1 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
96.2 M | $ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | USA |
 |
Alcon
ALC
|
10.4 B | $ 63.87 | 1.38 % | $ 31.5 B |  Schweiz |
 |
Becton, Dickinson and Company
BDX
|
21.8 B | $ 188.89 | 0.81 % | $ 54.3 B | USA |
 |
AtriCure
ATRC
|
535 M | $ 57.3 | 0.76 % | $ 2.74 B | USA |
 |
Baxter International
BAX
|
11.2 B | $ 24.8 | 0.46 % | $ 12.7 B | USA |
 |
electroCore
ECOR
|
32 M | $ 8.2 | 0.06 % | $ 69.6 K | USA |
 |
Glaukos Corporation
GKOS
|
507 M | $ 167.89 | 1.44 % | $ 9.6 B | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
320 M | $ 11.05 | 1.38 % | $ 459 M | USA |
 |
Haemonetics Corporation
HAE
|
1.33 B | $ 121.11 | 0.67 % | $ 5.71 B | USA |
 |
InfuSystem Holdings
INFU
|
143 M | $ 13.6 | 0.74 % | $ 281 M | USA |
 |
iRhythm Technologies
IRTC
|
747 M | $ 106.05 | 0.97 % | $ 3.39 B | USA |
 |
Intuitive Surgical
ISRG
|
10.1 B | $ 420.24 | 0.52 % | $ 150 B | USA |
 |
Repro Med Systems
KRMD
|
41.1 M | $ 3.11 | 3.67 % | $ 144 M | USA |
 |
LeMaitre Vascular
LMAT
|
250 M | $ 82.62 | 1.31 % | $ 1.87 B | USA |
 |
Milestone Scientific
MLSS
|
8.97 M | $ 0.34 | 1.34 % | $ 27.9 M | USA |
 |
Merit Medical Systems
MMSI
|
1.52 B | $ 87.16 | 0.18 % | $ 5.16 B | USA |
 |
Nephros
NEPH
|
18.8 M | $ 3.52 | 0.56 % | $ 37.4 M | USA |
 |
Envista Holdings Corporation
NVST
|
2.72 B | $ 22.82 | 0.75 % | $ 3.83 B | USA |
 |
Pulse Biosciences
PLSE
|
350 K | $ 46.32 | 7.66 % | $ 3.12 B | USA |
 |
ICU Medical
ICUI
|
2.23 B | $ 162.69 | 0.09 % | $ 4.01 B | USA |
 |
Pro-Dex
PDEX
|
77.5 M | $ 59.82 | 0.04 % | $ 193 B | USA |
 |
Repligen Corporation
RGEN
|
738 M | $ 178.2 | 1.58 % | $ 10 M | USA |
 |
ResMed
RMD
|
5.65 B | $ 235.29 | 0.11 % | $ 34.2 B | USA |
 |
Retractable Technologies
RVP
|
38.3 M | $ 0.59 | 0.8 % | $ 17.7 M | USA |
 |
STAAR Surgical Company
STAA
|
239 M | $ 21.84 | 1.58 % | $ 1.08 B | USA |
 |
STERIS plc
STE
|
5.94 B | $ 217.26 | 0.64 % | $ 21.3 B | USA |
 |
Stereotaxis
STXS
|
32.4 M | $ 1.05 | 2.7 % | $ 95.5 M | USA |
 |
Teleflex Incorporated
TFX
|
569 M | $ 123.29 | 0.35 % | $ 5.5 B | USA |
 |
Utah Medical Products
UTMD
|
9.04 M | $ 74.79 | 0.11 % | $ 242 M | USA |
 |
OraSure Technologies
OSUR
|
115 M | $ 3.71 | 0.51 % | $ 273 M | USA |
 |
West Pharmaceutical Services
WST
|
3.07 B | $ 374.65 | 0.77 % | $ 27.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.68 B | $ 8.44 | 0.29 % | $ 1.68 B | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 54.88 | 0.53 % | $ 10.9 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 0.99 | 0.49 % | $ 45.3 M |  Israel |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
71.6 M | - | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
1.43 M | - | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
2.09 B | - | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
125 K | - | - | $ 31.1 M | USA |